Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Surlorian - RyCarma Therapeutics

Next Previous
Search
Drug Profile

Surlorian - RyCarma Therapeutics

Alternative Names: ARM 210; S-48168

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARMGO Pharma
  • Developer National Institute of Neurological Disorders and Stroke; RyCarma Therapeutics; Servier
  • Class Heart failure therapies; Small molecules
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital structural myopathies; Polymorphic catecholergic ventricular tachycardia; Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Polymorphic catecholergic ventricular tachycardia
  • Phase I Congenital structural myopathies; Heart failure
  • No development reported Duchenne muscular dystrophy; Limb girdle muscular dystrophies; Sarcopenia; X-linked bulbo-spinal atrophy

Most Recent Events

  • 02 Apr 2025 Surlorian is still in phase I trial for Congenital structural myopathies in USA (PO) (NCT04141670)
  • 02 Apr 2025 Phase-I clinical trials in Heart failure (unspecified route), prior to April 2025 (RyCarma Therapeutics pipeline, April 2025)
  • 02 Apr 2025 RyCarma Therapeutics plans a phase II trial for Heart failure in 2026 (RyCarma Therapeutics pipeline, April 2025)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top